Association between β-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study.

Sophia Monica Humphries John Wallert Katarina Mars Claes Held Robin Hofmann Erik Martin Gustaf Olsson

Published in: European heart journal. Acute cardiovascular care (2022)

No difference in HRQoL was found among patients taking <50% vs. ≥50% of the target β-blocker dose, except for the EQ-VAS in which higher scores were reported in those taking a lower dose. The clinical meaningfulness of this statistical significance is likely low.

Keyphrases

angiotensin converting enzyme